193 related articles for article (PubMed ID: 10547391)
1. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
[TBL] [Abstract][Full Text] [Related]
2. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
[No Abstract] [Full Text] [Related]
3. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
5. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
6. Effect of fenretinide on ovarian carcinoma occurrence.
De Palo G; Mariani L; Camerini T; Marubini E; Formelli F; Pasini B; Decensi A; Veronesi U
Gynecol Oncol; 2002 Jul; 86(1):24-7. PubMed ID: 12079295
[TBL] [Abstract][Full Text] [Related]
7. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
[TBL] [Abstract][Full Text] [Related]
8. Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Piantadosi S
J Natl Cancer Inst; 1999 Nov; 91(21):1794. PubMed ID: 10547379
[No Abstract] [Full Text] [Related]
9. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
[TBL] [Abstract][Full Text] [Related]
11. Fenretinide and risk reduction of second breast cancer.
Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
[No Abstract] [Full Text] [Related]
12. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.
Lippman SM; Lee JJ; Karp DD; Vokes EE; Benner SE; Goodman GE; Khuri FR; Marks R; Winn RJ; Fry W; Graziano SL; Gandara DR; Okawara G; Woodhouse CL; Williams B; Perez C; Kim HW; Lotan R; Roth JA; Hong WK
J Natl Cancer Inst; 2001 Apr; 93(8):605-18. PubMed ID: 11309437
[TBL] [Abstract][Full Text] [Related]
13. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
Khuri FR; Lee JJ; Lippman SM; Kim ES; Cooper JS; Benner SE; Winn R; Pajak TF; Williams B; Shenouda G; Hodson I; Fu K; Shin DM; Vokes EE; Feng L; Goepfert H; Hong WK
J Natl Cancer Inst; 2006 Apr; 98(7):441-50. PubMed ID: 16595780
[TBL] [Abstract][Full Text] [Related]
15. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
Chlebowski RT; Blackburn GL; Thomson CA; Nixon DW; Shapiro A; Hoy MK; Goodman MT; Giuliano AE; Karanja N; McAndrew P; Hudis C; Butler J; Merkel D; Kristal A; Caan B; Michaelson R; Vinciguerra V; Del Prete S; Winkler M; Hall R; Simon M; Winters BL; Elashoff RM
J Natl Cancer Inst; 2006 Dec; 98(24):1767-76. PubMed ID: 17179478
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.
Macis D; Gandini S; Guerrieri-Gonzaga A; Johansson H; Magni P; Ruscica M; Lazzeroni M; Serrano D; Cazzaniga M; Mora S; Feroce I; Pizzamiglio M; Sandri MT; Gulisano M; Bonanni B; Decensi A
J Clin Oncol; 2012 Jan; 30(2):151-7. PubMed ID: 22162577
[TBL] [Abstract][Full Text] [Related]
17. Synthetic retinoid fenretinide in breast cancer chemoprevention.
Bonanni B; Lazzeroni M; Veronesi U
Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of breast cancer with fenretinide.
Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
[TBL] [Abstract][Full Text] [Related]
19. Fenretinide and cancer prevention.
Torrisi R; Decensi A
Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
[TBL] [Abstract][Full Text] [Related]
20. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
